Frequently Asked Questions for Somatic Cell Genome Editing FOAs
We appreciate your interest in the Somatic Cell Genome Editing funding opportunities and hope that you and your team will choose to submit an application. This list of frequently asked questions will be updated periodically as new questions from potential applicants are received.
- RFA-RM-18-014: $750,000 in FY19-20; $1.4M per year FY21-23
- RFA-RM-18-022: $415,000 per year FY19-22
- RFA-RM-18-023: $500,000 per year FY19-21 (UG3); $1M per year FY22 (UH3)
- RFA-RM-18-024: $250,000 per year FY19-22
- RFA-RM-18-025: $150,000 per year FY19-20 (UH2); $300,000 per year FY21-22 (UH3)
The funding announcements state that there will be data sharing among the consortium members and to the public through the DCC. Will my institution be able to protect its intellectual property developed through these cooperative agreements?
I’m interested in using genome editing to treat disease X. Can I propose the use of a disease-specific animal model as proof of concept studies in my application? Or do I have to use the reporter animals generated in the Consortium?
- Nervous System
- Cardiovascular System, including hematopoietic and immune cells
- Sensory Organs
- Endocrine system
- Lymphatic organs
- Gastrointestinal tract
Applications proposing delivery ex vivo will have a lower priority; in vivo is preferred. However, if the technology could do both, that is considered responsive.
- Greater capacity and versatility regarding the size and type of genome editing machinery delivered
- Reduced immunogenicity
- Avoidance of pre-existing immunity
- Improved or expanded cell-type targeting
- Simplification or increased scalability of production
- Less invasive mode of administration
- Support of transient or regulatable expression of genome editors
UG3/UH3 & UH2/UH3 (RM18-023 & -025) – Preliminary data are not required for these mechanisms, but may be included if available. Appropriate justification for the proposed work can be provided through literature citations, logic, and data from other sources.
UG3/UH3 & UH2/UH3 Mechanism (RM18-023 & -025): Milestones will be used to determine advancement into the UH3 phase for both award mechanisms. A clear go-/no-go transition milestone will designate this transition to the UH3 phase. Milestones can be negotiated between NIH program staff and the applicant.
For RM18-023, validation of in vivo delivery of genome editing machinery is key. The delivery awardee will work within the Consortium agreement to develop a protocol with the Small Animal Testing Center (RM18-012) in order to validate their delivery tool.
This page last reviewed on August 24, 2018